Androgen deprivation therapy: past, present and future

Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels.

(2017) W. U. Shipley et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide

(2012) Karol Axcrona et al.   BJU INTERNATIONAL

Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments

(2011) H Payne et al.   BRITISH JOURNAL OF CANCER

Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2–4 pN+ Prostate Cancer: Results of a Matched Analysis

(2011) Alberto Briganti et al.   EUROPEAN UROLOGY

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

(2011) Nicolas Mottet et al.   EUROPEAN UROLOGY

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study

(2011) Tanya B. Dorff et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

(2011) E. David Crawford et al.   JOURNAL OF UROLOGY

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

(2011) Padraig Warde et al.   LANCET

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

(2011) James W Denham et al.   LANCET ONCOLOGY

Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer

(2011) Christopher U. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy? A Systematic Review

(2010) Paul C.M.S. Verhagen et al.   EUROPEAN UROLOGY

Predictors of Androgen Deprivation Therapy Efficacy Combined With Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose

(2010) Scott Williams et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

(2010) Michel Bolla et al.   LANCET ONCOLOGY

Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients

(2009) Guo-Wen Lin et al.   ASIAN JOURNAL OF ANDROLOGY

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study

(2009) Fritz H. Schröder et al.   BJU INTERNATIONAL

Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy

(2009) Juan Morote et al.   BJU INTERNATIONAL

Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: A systematic review and meta-analysis of randomised trials

(2009) M.D. Shelley et al.   CANCER TREATMENT REVIEWS

Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

(2009) Bertrand Tombal et al.   EUROPEAN UROLOGY

Is Biochemical Response More Important Than Duration of Neoadjuvant Hormone Therapy Before Radiotherapy for Clinically Localized Prostate Cancer? An Analysis of the 3- Versus 8-Month Randomized Trial

(2009) Abraham Alexander et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

(2009) Wennuan Liu et al.   NATURE MEDICINE

Duration of Androgen Suppression in the Treatment of Prostate Cancer

(2009) Michel Bolla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975–2004

(2008) Sabina Hussain et al.   BJU INTERNATIONAL

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

(2008) Laurence Klotz et al.   BJU INTERNATIONAL

A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma

(2008) M.D. Shelley et al.   CANCER TREATMENT REVIEWS

Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)

(2008) Fritz H. Schröder et al.   EUROPEAN UROLOGY

Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer

(2008) Anthony V. D’Amico et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

(2008) Mack Roach et al.   JOURNAL OF CLINICAL ONCOLOGY

Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

(2008) Eric M. Horwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

(2008) Anders Widmark et al.   LANCET

Will GnRH antagonists improve prostate cancer treatment?

(2008) Ilpo Huhtaniemi et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?

(2008) Hendrik van Poppel et al.   UROLOGY

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen-Deprivation Therapy

(2007) Bertrand Tombal et al.   EUROPEAN UROLOGY SUPPLEMENTS

Prediction of Survival of Metastatic Prostate Cancer Based on Early Serial Measurements of Prostate Specific Antigen and Alkaline Phosphatase

(2007) David Robinson et al.   JOURNAL OF UROLOGY